These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10950795)

  • 1. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
    Binley JM; Trkola A; Ketas T; Schiller D; Clas B; Little S; Richman D; Hurley A; Markowitz M; Moore JP
    J Infect Dis; 2000 Sep; 182(3):945-9. PubMed ID: 10950795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of HAART on humoral immune response in primary HIV-1 infected patients.
    Pastori C; Barassi C; Lillo F; Longhi R; Capiluppi B; Nozza S; Galli A; Uberti-Foppa C; Lazzarin A; Tambussi G; Lopalco L
    J Biol Regul Homeost Agents; 2002; 16(1):9-17. PubMed ID: 12003182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.
    Kim JH; Mascola JR; Ratto-Kim S; VanCott TC; Loomis-Price L; Cox JH; Michael NL; Jagodzinski L; Hawkes C; Mayers D; Gilliam BL; Birx DC; Robb ML
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1021-34. PubMed ID: 11485619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.
    Notermans DW; de Jong JJ; Goudsmit J; Bakker M; Roos MT; Nijholt L; Cremers J; Hellings JA; Danner SA; de Ronde A
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1003-8. PubMed ID: 11485617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy.
    Kimura T; Yoshimura K; Nishihara K; Maeda Y; Matsumi S; Koito A; Matsushita S
    J Infect Dis; 2002 Jan; 185(1):53-60. PubMed ID: 11756981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial.
    Hoen B; Dumon B; Harzic M; Venet A; Dubeaux B; Lascoux C; Bourezane Y; Ragnaud JM; Bicart-See A; Raffi F; Beauvais L; Fleury H; Séréni D
    J Infect Dis; 1999 Oct; 180(4):1342-6. PubMed ID: 10479169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
    Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
    J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
    Kumar A; Buch S; Foresman L; Bischofberger N; Lifson JD; Narayan O
    Virology; 2001 Jan; 279(1):97-108. PubMed ID: 11145893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.
    Binley JM; Schiller DS; Ortiz GM; Hurley A; Nixon DF; Markowitz MM; Moore JP
    J Infect Dis; 2000 Apr; 181(4):1249-63. PubMed ID: 10762561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children.
    Kumar S; Batra H; Singh S; Chawla H; Singh R; Katpara S; Hussain AW; Das BK; Lodha R; Kabra SK; Luthra K
    J Gen Virol; 2020 Dec; 101(12):1289-1299. PubMed ID: 32915123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drugs: amprenavir and abacavir.
    TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
    Zaunders JJ; Kaufmann GR; Cunningham PH; Smith D; Grey P; Suzuki K; Carr A; Goh LE; Cooper DA
    J Infect Dis; 2001 Mar; 183(5):736-43. PubMed ID: 11181150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.
    Equils O; Garratty E; Wei LS; Plaeger S; Tapia M; Deville J; Krogstad P; Sim MS; Nielsen K; Bryson YJ
    J Infect Dis; 2000 Sep; 182(3):751-7. PubMed ID: 10950768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
    J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy.
    Wang FX; Kimura T; Nishihara K; Yoshimura K; Koito A; Matsushita S
    J Infect Dis; 2002 Mar; 185(5):608-17. PubMed ID: 11865417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
    Markowitz M; Vesanen M; Tenner-Racz K; Cao Y; Binley JM; Talal A; Hurley A; Jin X; Chaudhry MR; Yaman M; Frankel S; Heath-Chiozzi M; Leonard JM; Moore JP; Racz P; Nixon DF; Ho DD
    J Infect Dis; 1999 Mar; 179(3):527-37. PubMed ID: 9952358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.